In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.
The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa. Aztreonam in combination with amikacin demonstrated synergy against 71% of the isolates, whereas combinations of aztreonam plus a second beta-lactam demonstrated synergy against 42% of the isolates.
D000583:Amikacin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam; D001424:Bacterial Infections / Q000382:microbiology; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D007612:Kanamycin; D000583:Amikacin; D001398:Aztreonam